---
title: "BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273249966.md"
datetime: "2026-01-21T15:00:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273249966.md)
  - [en](https://longbridge.com/en/news/273249966.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273249966.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273249966.md) | [繁體中文](https://longbridge.com/zh-HK/news/273249966.md)


# BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances

Shares of biotech firm Aligos Therapeutics (ALGS.O) up 3% at $8.25 Co says it is testing its experimental hepatitis B drug, pevifoscorvir sodium, aimed at blocking virus replication, in a mid-stage study with 144 patients

Expects first interim data from study in early 2026, main results in 2027

ALGS says earlier tests showed the oral drug reduced infection markers

Separately, co announced that its chief medical officer, Dr Hardean Achneck, has resigned and a search for a successor is underway

ALGS was down ~25% in 2025

### Related Stocks

- [Aligos Therapeutics, Inc. (ALGS.US)](https://longbridge.com/en/quote/ALGS.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/en/news/278565253.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/en/news/278448836.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/en/news/278778570.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md)
- [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/en/news/278917368.md)